new fda ruling on tirzepatide Breaking News: Compounding Pharmacies Take the Fight to the Fifth Circuit The Outsourcing Facilities Association (OFA) has filed an appeal challenging the FDA's decision to restrict compounding pharmacies from producing tirzepatide, the Tirzepatide Lawsuit Against the FDA:

Also, if you feel warmer than usual, tell your doctor right away

Zhang, K., Chen, H

Its like having a built-in portion control system

Just pick a consistent day that works for you

It is important to note that neurological damage can occur before haematological changes become apparent, and symptom severity does not always correlate with the degree of biochemical deficiency

Figure 2: Novel Incretin Mimetic Assets for T2DM and Obesity in Phase 2/3 of Development Remaining Unmet Needs Remaining Unmet Needs Though the value proposition of on-market GLP-1 and dual-agonists is strong, several key unmet needs still exist for incretin mimetics across diabetes and obesity, namely: (1) improved efficacy, (2) better tolerability, (3) more convenient options / alternative ROAs, and (4) improved access and affordability